Cassava Sciences Inc News - SAVA

	Real-time Prices	Level 2
Canadian Securities Exchange

Professional-Grade Tools, for Individual Investors.

Premium

Cassava Sciences Names Rick Barry as Chief Executive Officer

AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology...

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage...

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC...

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the...

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage...

👍️0

FACT-MASTER 1 hour ago

Reminds me of of ARGS - that was a stinging lesson for me, ouch...still hurts!

Although i feel bad for investors in SAVA, biotech is high risk and that should be understood by all investors. Lawsuit won't help imo, ... prove wrongdoing against forward looking statements, etc, etc, for 5+ years, imo. - only good for the lawyers, imo.

Ref: Argos Therapeutics

👍️0

TheFinalCD 2 hours ago

https://x.com/MartinShkreli/status/1859681514415607930

👍️0

MartinLutherKing 5 hours ago

You will all kiss my feet brothers make it all back

👍️0

MartinLutherKing 6 hours ago

Get ready for Fda fast track status for nobel prize micro rna for terminally ill cancer patients

👍️0

MartinLutherKing 6 hours ago

A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.

👍️0

PonkenPlonken 6 hours ago

I have never ever in my life seen a great bio with a chart like this.
SCREAMS promotion campaign - which is something you dont do when you have the next greatest thing in oncology.
Now a 1 for 33 is coming??

"The reverse split will reduce the number of shares of common stock outstanding from 17,265,658 shares to approximately 523,202 shares." per their recent PR. They want to cater to the low float crowd.
A more healthy ratio wouldve done it too...

👍️0

MartinLutherKing 6 hours ago

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 23 2024 - 7:00AM

Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the second cohort of patients based on its favorable review of Cohort 1 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. All patients in the first cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. The dose administered to the second cohort will be approximately double the dose administered to the first cohort.
“An SRC is a group of clinicians and experts that oversee the safety of subjects during the conduct of the trial. The SRC makes decisions on whether and how the study should proceed, including dose escalation and de-escalation decisions per the study design. The recommendations of the SRC are used to decide whether a clinical trial should be continued as designed, changed, or terminated,” commented Sue Duggan, TransCode’s Senior Vice President of Operations. Duggan added, “No dose-limiting toxicities were reported in the first cohort of patients treated with TTX-MC138. Eligible subjects may now be scheduled in Cohort 2 for treatment with the next dose level of TTX-MC138.”

👍️0

MartinLutherKing 6 hours ago

Is FDA And NIH Ascam
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 05 2024 - 7:00AM

Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.

The clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138. While efficacy of TTX-MC138 is not an endpoint in this trial, the trial may nevertheless provide early evidence of TTX-MC138 clinical activity in patients with metastatic disease. Funds under the grant are expected to be received over two years.

“We are honored that the NIH recognizes and continues to support our mission to advance therapies against metastatic cancer,” said Zdravka Medarova, Ph.D., Chief Scientific Officer of TransCode. “NIH funding is awarded only after rigorous review. We believe that this award attests to the potential impact, novelty, and robustness of the TTX-MC138 clinical development program.”

TTX-MC138 is a first-in-class therapeutic candidate with novel relevance to metastatic disease. Successful clinical development of TTX-MC138 potentially represents a viable treatment option for many patients with metastatic cancer.

👍️0

MartinLutherKing 6 hours ago

RNAZ FDA Fast track status in progress, they are making everyone panic sell, read between the lines brother, you will kiss my feet and make all your $$ back and more

👍️0

PonkenPlonken 6 hours ago

I was short SAVA.
And believe RNAZ is a scam.

👍️ 1

MartinLutherKing 7 hours ago

last call for RNAZ cancer cure fda fast track coming about to unleash hell on shorts

👍️0

rbl100 7 hours ago

Good. But I am glad I sold @ $4.26 yesterday. I am not a member of Congress who gets info. and can inside trade. Ever wonder how a women who's net worth was $319,000 joins Congress and in 4 years her net worth is now $46 Million? They get into Congress and are allowed to inside trade. That's how.

👍️0

rbl100 7 hours ago

Correct. But there is no one home.

👍️0

PonkenPlonken 8 hours ago

I agree. I was very fortunate to learn from a professional in the bio sector. He taught me that its crucial to understand whats actually being discussed in the share price.
Sometimes, you have very seggsy risk reward ratios......... Where stocks correct upwards.

👍️ 1

John_Vallay 8 hours ago

This is the world we live in when it comes to biotech investing.
Every day is a positive day as long as the company is moving forward and trying to get data that shows promising results. During this long period some stocks go up, some go down but the positivity and promise is there for all investors to hold onto and keep the dream alive.

Then the data comes out and it is not good, or FDA says no.

That is biotech investing - purely speculative with absolutely no control by the management team, other than hurting the stock price during the process with poor deals that are some form of toxic financing.

Biotech investing is not for the faint of heart.

👍️0

PonkenPlonken 9 hours ago

Just in: SRPT to give 850mn upfront in partnership with ARWR...
Another AAV based gene tx seeking RNAI......

👍️0

PonkenPlonken 9 hours ago

I dont know much about Rett but I like their miRARE + aav9 to manage precise mecp2 expression... I like this RNA thermometer/thermostat function. I believe its the way to go.
Whether they will succeed or the stock go up? I dont know.

👍️0

nsomniyak 9 hours ago

I agree that there was no problem in the way the Ph3 readout was handled (obviously the content was not positive).

My sense is that SAVA did nothing wrong but there will be class action suits anyway because there always are when a stock drops precipitously.

It is puzzling why the Ph 3 was so blah given the positive results in earlier phases. SAVA lying about earlier results is one possibility, but I think not overly likely. Possibly some selective reporting. Doesn't really matter at this point. These class action lawsuits never proceed to an actual trial where evidence is presented and evaluated. They are always settled out of court with a denial of wrongdoing. If anything SAVA holders will see pennies on the dollar several years from now. Sadly, there will be no full recovery of losses and, apparently, no meds from SAVA for AD patients (even worse).

👍️ 1

MartinLutherKing 10 hours ago

SAVA Make it all back with RNAZ cancer destruction fast track news for terminally ill cancer patients coming

👍️0

PonkenPlonken 11 hours ago

We do not know enough yet. This ph3 readout wasnt problematic in any way legally speaking.

The question is whether these ph3 results mean they MUST have lied at some point prior. And to what extent.

👍️0

PonkenPlonken 11 hours ago

partnerships and buyouts...
You need very serious edge to play these. Its possible for mortals to anticipate a partner in a ph1/ph2 company when their data is about to be due and a BP dropped similar but not equal programs recently - everything else i would never try to factor in. Leave to the pros.

👍️0

nsomniyak 12 hours ago

Of course there will be class action lawsuits against SAVA - that is what class action lawyers do.

👍️0

FACT-MASTER 20 hours ago

Thank you very much for your input.

I like ESPR as well and concur that VRNA is a good comparable.
I think ESPR could move quickly ( 2025) as you mentioned it is a BIG space.

https://www.esperion.com/news-releases/news-release-details/us-fda-approves-broad-new-labels-nexletolr-and-nexlizetr-prevent

The next sign most shareholders are looking for is a U.S. partnership / Canada - Australia filing / and of course the ultimate - a buyout.

2024 imo, has been a milestone year for ESPR, however the market appears skeptical. Hopefully script growth continues / revenue continues to grow, just not sure if mgmt. can execute as it should.

( I came across ESPR as i was reviewing a litigation case Esperion vs. Daiichi Sankyo Europe about 1 year ago. That case settled in January/24 - i viewed that as a pivotal positive and credit to ESPR mgmt. )

👍️ 1

dinogreeves 20 hours ago

Charity starts from home.

👍️0

georgejjl 21 hours ago

From Adam F.

Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
While many investors lost money, the bigger tragedy involves patients

Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more than a placebo in a large clinical trial.

The negative outcome is devastating for the nearly 2,000 participants in this study and a second study also shut down Monday. Clinical trials in Alzheimer’s fail all too frequently, but simufilam was built on falsified research and misleading efficacy claims. The drug should never have advanced this far.

https://www.statnews.com/2024/11/25/cassava-sciences-simufilam-trial-failure/

GOD bless,

👍️ 1

MartinLutherKing 21 hours ago

FDA green light RNAZ explosion coming brothers Live the dream

👍️0

MartinLutherKing 22 hours ago

SAVA Hold the line brothers RNAZ Green light cancer cure is coming get it all back

👍️0

dinogreeves 24 hours ago

Can you handle the truth? Yes it is and was since the dawn of times. VCN*X has one of the best science in this space.

👍️0

Banjo50 1 day ago

IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!

👍️0

rbl100 1 day ago

I don't know. But I do know there is talk of lawsuits against them now. The cash on hand and assets is meaningless and they ended all research going forward. I could not risk it. Put one $Thousand into this and got nervous LOL. Was up $124 this morning, but ended up selling for only $24 profit. Better than getting stuck !

👍️0

runncoach 1 day ago

I thought the same. There was news on Government AD funding that day but still strange

👍️0

FooBarAndGrill 1 day ago

OK, What could it be?
ASSETS $224M Dividend by SHARES 48M = $4.66

👍️0

tredenwater2 1 day ago

Todays drop makes the recent trade last week even more suspicious. Did someone get out and shorts piling in at the same time ahead of news?

👍️0

rbl100 1 day ago

Got out. Can't risk it. You can't fight criminal shorters. This is why we need the uptick rule back and shorting made illegal - period.

👍️0

rbl100 1 day ago

82m shares traded 48m outstanding🤔🤫

👍️0

FooBarAndGrill 1 day ago

re. "gene therapy"
Do you follow $TSHA?
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

👍️0

PonkenPlonken 1 day ago

I like ESPR, think lower LDL-C is a really important health factor that is still underappreciated. But whether the stock will go anywhere - I cant tell. I would want to wait for a sign.
VRNA is company that did very well post approval. This one could be similar as they fill a BIG space with lots of unmet need for a few years until there will be a better option approved. I usually do oncology and gene therapy and look at clinical companies...

👍️ 1

rbl100 1 day ago

oversold

shorts covered and now are finito. way oversold. financials did not change.

👍️0

FACT-MASTER 1 day ago

Have a glance at ESPR.

Would be interested in your opinion on that one.

thank you.

👍️ 1

PonkenPlonken 1 day ago

No this is VERY Good for patients with AD.
They have been deliberately lied to by SAVA. They had their hopes raised via false promises. While SAVA KNEW they had nothing to offer. UGLY and criminal. Now they can seek a drug that actually helps them.
Quit trying to spin it...

👍️0

FooBarAndGrill 1 day ago

Shorts are closing out. Adios.

👍️0

Stockexpertpro 1 day ago

SAVA 47% Float Sold Short Squeeze them force them to cover currently down huge

👍️0

tredenwater2 1 day ago

Ouch. Tough day for people with AD and investors. No one likes to see this market open except shorts.

👍️0

WebSlinger 1 day ago

Ivermectin has shown some promise with dementia / Alzheimer's. Hopefully, someone will take the time to do a study.

PonkenPlonken 1 day ago

I am so so gleeful today-------- guilt free!
NO MORE LIES!

👍️0

WebSlinger 1 day ago

In the last quarterly 10-Q financial, they had about $149 MILLION in cash.

What happens to that?

Sounds like there will be a class action suit coming in the next few days...

👍️0

PonkenPlonken 1 day ago

Oh this is VERY VERY good for the patients. Now they can look for a compound that actually helps them

👍️ 1

FooBarAndGrill 1 day ago

Yep.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Cassava Sciences Inc (SAVA)

Professional-Grade Tools, for Individual Investors.

SAVA News

Cassava Sciences Names Rick Barry as Chief Executive Officer

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

Cassava Sciences Announces Expansion of Open-Label Extension Trials

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

Cassava Sciences Issues Statement on Former Science Advisor

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

Redemption Date Announced for Warrants

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

SAVA Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for Canadian Securities Exchange (CSE) Level 1 and 2

1 year 40%, 2 years 40% and *3 years 60%

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Cassava Sciences Inc (SAVA) News

Cassava Sciences Inc (SAVA)

Professional-Grade Tools, for Individual Investors.

SAVA News

Cassava Sciences Names Rick Barry as Chief Executive Officer

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

Cassava Sciences Announces Expansion of Open-Label Extension Trials

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

Cassava Sciences Issues Statement on Former Science Advisor

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

Redemption Date Announced for Warrants

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

SAVA Discussion

Your Recent History

Company

Business

Popular

Get The App

BLACK FRIDAY

Save up to 60%* for Canada: TSX and TSXV Level 1

1 year 40%, 2 years 40% and *3 years 60%